The treatment of demoralisation, apathy and hypoactive delirium in somatic illness using methylphenidate;De behandeling met methylfenidaat van demoralisatie, apathie en hypoactief delier bij patiënten met een somatische ziekte

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 35, 2004, Pages 1738-1741

  Meyers, B J F ^a   Van Ojen, R L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ADULT; AGED; APATHY; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CLINICAL FEATURE; DELIRIUM; DEPRESSION; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PROGNOSIS; PSYCHOSOMATIC DISORDER; TRAFFIC ACCIDENT; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; CENTRAL NERVOUS SYSTEM STIMULANTS; DELIRIUM; DEPRESSION; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; METHYLPHENIDATE; MIDDLE AGED; MULTIPLE MYELOMA; PALLIATIVE CARE; PROGNOSIS; SOMATOFORM DISORDERS; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 4444222588     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Stoudemire A, Fogel BS, Greenberg DB. Psychiatric care of the medical patient. 2nd ed. New York: Oxford University Press; 2000.
2. Rundell J, Wise M. Textbook of consultation-liaison psychiatry. Washington, D.C.: American Psychiatric Press; 1996.
3. College voor zorgverzekeringen. Farmacotherapeutisch kompas. Diemen: College voor zorgverzekeringen; 2004. p. 129.
4. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists. In: Goodman & Gilman's The pharmacologic basis of therapeutics. 8th ed. New York: Pergamon Press; 1990. p. 187-220.
5. Stedman's medical dictionary. Boston: Houghton Mifflin; 1995.
6. Drug information for health care and professionals. 19th ed. Englewood: Micromedex; 1999.
7. Schweri MM, Skolnick P, Rafferty MF, Rice KC, Janowsky AJ, Paul SM. [3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J Neurochem 1985; 45:1062-70.
8. Janowsky A, Schweri MM, Berger P, Long R, Skolnick P, Paul SM. The effects of surgical and chemical lesions on striatal [3H]threo-(+/-)- methylphenidate binding: correlation with [3H]dopamine uptake. Eur J Pharmacol 1985;108:187-91.
9. Hurd YL, Ungerstedt U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol 1989;166:251-60.
10. Butcher SP, Liptrot J, Aburthnott GW. Characterisation of methylphenidate and nomifensine induced dopamine release in rat striatum using in vivo brain microdialysis. Neurosci Lett 1991;122:245-8.
11. Wall SC, Gu H, Rudnick G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 1995; 47:544-50.
12. Volkow ND, Wang GJ, Gatley SJ, Fowler JS, Ding YS, Logan J, et al. Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. Psychopharmacologia 1996;123:26-33.
13. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999;283:397-401.
14. Faraj BA, Israili ZH, Perel JM, Jenkins ML, Holtzman SG, Cucinell SA, et al. Metabolism and disposition of methylphenidate-14C: studies in man and animals. J Pharmacol Exp Ther 1974;191:535-47.
15. Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA, et al. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 1983;226:382-6.
16. Cassem NH. In: Hackett TP, Cassem NH, editors. Handbook of general hospital psychiatry. Massachusetts: PSG Publishing Company; 1987. p. 245.
17. Holmes VF. Medical use of psychostimulants: an overview. Int J Psychiatry Med 1995;25:1-19.
18. Woods SW, Tesar GE, Murray GB, Cassem NH. Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry 1986;47:12-5.
19. Masand P, Pickett P, Murray GB. Psychostimulants for secondary depression in medical illness. Psychosomatics 1991;32:203-8.
20. Nederlandse Vereniging voor Psychiatrie (NVP). Multidisciplinaire richtlijn delirium 2004. Amsterdam: Boom [ter perse].
21. American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999;156(Suppl):1-20.
22. Standards of Practice Committee of the American Sleep Disorders Association. Practice parameters for the use of stimulants in the treatment of narcolepsy. Sleep 1994;17:348-51.
23. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994; 17:352-71.
24. Lavretsky H, Kim MD, Kumar A, Reynolds 3rd CF. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry 2003;64:1410-4.
25. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996;57:72-6.
26. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 2001; 9:298-303.
27. Bruera E, Chadwick S, Brenneis C, Hanson J, MacDonald RN. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987;71:67-70.
28. Wilwerding MB, Loprinzi CL, Mailliard JA, O'Fallon JR, Miser AW, Haelst C van, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 1995;3:135-8.
29. Ivy AC, Goetzl FR, Burrill DY. Morphine-dextro-amphetamine analgesia. Med War 1944;6:67-71.
30. Forrest jr WH, Brown jr BW, Brown CR, Defalque R, Gold M, Gordon HE, et al. Dextroamphetamine with morphine for the treatment of postoperative pain. N Engl J Med 1977;296:712-5.
31. Dalal S, Melzack R. Psychostimulant drugs potentiate morphine analgesia in the formalin test. J Pain Symptom Manage 1998;16:230-9.
32. Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. A reconsideration. Arch Gen Psychiatry 1987;44:286-95.
33. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical review. J Clin Psychiatry 1989;50:241-9.
34. Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995;152:929-31.
35. Fernandez F, Adams F, Holmes VF, Leny JK, Neidhart M. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics 1987;28:455-61.
36. Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med 1984;46:199-212.
37. Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manage 1998;16:193-8.
38. Weitzner MA, Meyers CA, Valentine AD. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 1995;7:347-50.
39. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998;16:2522-7.
40. Morita T, Otani H, Tsunoda J, Inoue S, Chihara S. Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. Support Care Cancer 2000;8:134-7.
41. Spreeuwenberg C, Bakker DJ. Handboek palliatieve zorg. Maarssen: Elsevier Gezondheidszorg; 2002.
42. IKMN oncologieboek 2002. Richtlijnen palliatieve zorg. Utrecht: Integraal Kankercentrum Midden-Nederland; 2002.
43. Fernandez F, Levy JK, Galizzi H. Response of HIV-related depression to psychostimulants: case reports. Hosp Community Psychiatry 1988;39:628-31.
44. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002;14:461-2.
45. Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998;79:1047-50.
46. Martinsson L, Wahlgren NG. Safety of dexamphetamine in acute ischemic stroke: a randomized, double-blind, controlled dose-escalation trial. Stroke 2003;34:475-81.
47. Sonde L, Nordstrom M, Nilsson CG, Lokk J, Viitanen M. A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke. Cerebrovasc Dis 2001;12:253-7.
48. Watanabe MD, Martin EM, DeLeon OA, Gaviria M, Pavel DG, Trepashko DW. Successful methylphenidate treatment of apathy after subcortical infarcts. J Neuropsychiatry Clin Neurosci 1995;7:502-4.
49. Laurence DR, Bennett PN. Clinical pharmacology. 5th ed. New York: Churchill Livingstone; 1980. p. 506-46.
50. Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am 1996;19:515-47.
51. Marsh LD, Key JD, Payne TP. Methylphenidate misuse in substance abusing adolescents. J Child Adolescent Substance Abuse 2000;9:1-14.
52. Haglund RM, Howerton LL. Ritalin: consequences of abuse in a clinical population. Int J Addict 1982;17:349-56.